Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anidulafungin vs Caspofungin in Neutropenic Patients with Invasive Candida Infection
NCT00806351Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Aug 2009
- Primary completion
- Oct 2011
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of anidulafungin in invasive candidiasis (2 arms), sponsored by Pfizer. Primary endpoint: Global Response at End of Intravenous Treatment. Started Aug 2009; status: terminated.
02
Drugs
anidulafungin
03
Conditions
invasive candidiasis
Beyond the preview
Go deeper on NCT00806351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00806351.